Pacira Pharmaceuticals (PCRX) Needs a Hail Mary Hockeystick After August - Jefferies
Tweet Send to a Friend
Jefferies analyst David Steinberg reiterated a Buy rating and $85.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE